UK MHRA Approves GSK’s BLENREP® in Combination with BVd and BPd for the Treatment of Adult RRMM Patients
UK Medicine and Healthcare products Regulatory Agency (MHRA) authorizes use of Blenrep (belantamab mafodotin) for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.
